SALT LAKE CITY — Ibrutinib appeared safe and effective for children with previously untreated or relapsed/refractory chronic graft-versus-host disease, according to study results.
Paul A. Carpenter, MD, professor at Fred Hutchinson Cancer Research Center, presented the results at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
“Chronic GVHD is a potentially debilitating life-threatening complication of allogeneic [hematopoietic stem cell transplantation],” Carpenter said during a presentation. “There are limited treatment options